Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Mr. Peter W. Williams

Vice President of Human Resources

Dr. George A. Gaitanaris M.D., Ph.D.

Chief Scientific Officer & Vice President of Science

Mr. Peter B. Cancelmo J.D.

Vice President, General Counsel & Corporate Secretary

Dr. Andreas  Grauer M.D.

Vice President & Chief Medical Officer

Dr. Pamela Pierce Palmer M.D., Ph.D.

Co-Founder

Mr. Michael A. Jacobsen

Chief Accounting Officer, Vice President of Finance & Treasurer

Dr. Gregory A. Demopulos M.D.

Co-Founder, Chairman, Chief Executive Officer & President

Dr. Catherine A. Melfi Ph.D.

Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems

Ms. Nadia  Dac

Vice President & Chief Commercial Officer

Биотехнологии

Omeros Corporation

Omeros Corporation Структура управления

Информация о руководстве